|
UBE2L3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.90369950306513E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.60130000370629E-08 |
| Normal-vs-Stage2 |
1.164140E-02 |
| Normal-vs-Stage3 |
6.85519999654716E-08 |
| Normal-vs-Stage4 |
8.46830000011956E-07 |
| Stage1-vs-Stage2 |
9.510800E-01 |
| Stage1-vs-Stage3 |
3.986800E-01 |
| Stage1-vs-Stage4 |
5.715700E-02 |
| Stage2-vs-Stage3 |
6.888600E-01 |
| Stage2-vs-Stage4 |
2.301400E-01 |
| Stage3-vs-Stage4 |
2.233200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.45269996032482E-09 |
| Normal-vs-AfricanAmerican |
4.986400E-04 |
| Normal-vs-Asian |
3.658000E-03 |
| Caucasian-vs-AfricanAmerican |
1.107010E-01 |
| Caucasian-vs-Asian |
6.066800E-01 |
| AfricanAmerican-vs-Asian |
9.341700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.71659000000046E-05 |
| Normal-vs-Female |
4.9104054156146E-11 |
| Male-vs-Female |
5.924600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.91910000008266E-08 |
| Normal-vs-Age(41-60Yrs) |
2.03109999930007E-08 |
| Normal-vs-Age(61-80Yrs) |
2.35649999957843E-07 |
| Normal-vs-Age(81-100Yrs) |
6.448800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.263600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.616200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.028300E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.738200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.814250E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.058600E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.605800E-01 |
| Classical-VS-Follicular |
2.676100E-02 |
| Classical-VS-Other |
5.925200E-01 |
| Classical-VS-Normal |
3.28310000297094E-08 |
| Tall-VS-Follicular |
6.181600E-02 |
| Tall-VS-Other |
5.674000E-01 |
| Tall-VS-Normal |
3.198500E-03 |
| Follicular-VS-Other |
9.604800E-01 |
| Follicular-VS-Normal |
1.16790000004308E-07 |
| Other-VS-Normal |
2.180800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.8918000055379E-08 |
| Normal-vs-N1 |
1.56630000003322E-06 |
| N0-vs-N1 |
2.802800E-01 |
|
|
